Victor Levin

Victor Levin

UNVERIFIED PROFILE

Are you Victor Levin?   Register this Author

Register author
Victor Levin

Victor Levin

Publications by authors named "Victor Levin"

Are you Victor Levin?   Register this Author

67Publications

1043Reads

30Profile Views

How far will the Voyager take us?

Authors:
Victor A Levin

CNS Oncol 2019 03 15;8(1):CNS26. Epub 2019 Feb 15.

Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77005, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/cns-2018-0019DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499013PMC
March 2019

Clinical importance of eflornithine (α-difluoromethylornithine) for the treatment of malignant gliomas.

CNS Oncol 2018 04 30;7(2):CNS16. Epub 2018 Jan 30.

Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030-4009, USA.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/cns-2017-0031
Publisher Site
http://dx.doi.org/10.2217/cns-2017-0031DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5977277PMC
April 2018

Understanding brain penetrance of anticancer drugs.

Neuro Oncol 2018 04;20(5):589-596

UCLA Brain Tumor Imaging Laboratory, Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noy018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892153PMC
April 2018

Drug discovery in neuro-oncology: challenges in the path forward.

Authors:
Victor A Levin

Neuro Oncol 2018 03;20(4):435-436

Department of Neuro-Oncology, MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noy004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909643PMC
March 2018

Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab.

J Neurooncol 2017 Sep 19;134(2):325-330. Epub 2017 Jun 19.

Edwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-017-2528-3DOI Listing
September 2017

CNS Anticancer Drug Discovery and Development: 2016 conference insights.

CNS Oncol 2017 Jul 18;6(3):167-177. Epub 2017 Jul 18.

Albany College of Pharmacy & Health Sciences, Albany, NY 12208, USA (J.M.G.).

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/cns-2017-0014
Publisher Site
http://dx.doi.org/10.2217/cns-2017-0014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6009211PMC
July 2017

Personalized medicine in neuro-oncology.

Authors:
Victor A Levin

CNS Oncol 2016 21;5(2):55-8. Epub 2016 Mar 21.

Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/cns-2016-0006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047424PMC
October 2016

CNS Anticancer Drug Discovery and Development Conference White Paper.

Neuro Oncol 2015 Nov;17 Suppl 6:vi1-26

Kaiser Permanente, Redwood City, California, USA (V.A.L.); University of Texas MD Anderson Cancer Center, Houston, TX, USA (V.A.L.); University of California, San Francisco, CA, USA (V.A.L.); SUNY Stony Brook University, Stony Brook, NY, USA (P.J.T.); Icahn School of Medicine at Mount Sinai, New York, NY, USA (J.M.G., M.R.B., A.C.D.); Columbia University Institute for Cancer Genetics, New York, NY, USA (A.I.); Fred Hutchinson Cancer Research Center, Seattle, WA, USA (P.J.P.); Genentech, Inc., South San Francisco, CA, USA (T.P.H.); University of Minnesota School of Pharmacy, Minneapolis, MN, USA (W.F.E.); Angiochem, Inc., Montreal, Quebec, Canada (J.E.L.); Pfizer Oncology, San Diego, CA, USA (T.W.J.); Massachusetts Institute of Technology, Cambridge, MA, USA (F.M.W.); US Food and Drug Administration, Silver Spring, MD, USA (J.S.); Texas Tech University School of Pharmacy, Amarillo, TX, USA (Q.R.S., R.S.); NewGen Therapeutics, Inc., Menlo Park, CA, USA (W.S.); Mayo Clinic, Rochester, MN, USA (J.N.S.); Dana-Farber Cancer Institute, Boston, MA, USA (P.Y.W.); University of Texas MD Anderson Cancer Center, Houston, TX, USA (D.A.B.); Celgene Avilomics Research, Bedford, MA, USA (R.C.P.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nov169DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4581696PMC
November 2015

Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for PCV.

Authors:
Victor A Levin

Oncology (Williston Park) 2015 Apr;29(4):264, 266-8

View Article

Download full-text PDF

Source
April 2015

Impact of bevacizumab administered dose on overall survival of patients with progressive glioblastoma.

J Neurooncol 2015 Mar 11;122(1):145-50. Epub 2015 Jan 11.

Department of Neurosurgery and Neuroscience, Kaiser Permanente, 1150 Veterans Boulevard, Redwood City, CA, 94063, USA,

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11060-014-1693-x
Publisher Site
http://dx.doi.org/10.1007/s11060-014-1693-xDOI Listing
March 2015

Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma.

Neuro Oncol 2015 Feb 19;17(2):266-73. Epub 2014 Sep 19.

Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas (M.P.-P., M.D.G., V.A.L., J.F.D.G., C.A.C., M.E.L., W.K.A.Y., M.R.G.); Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas (K.R.H.); General Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas (M.J.F., L.W.L.); Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas (A.M.); Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas (K.D.A); Department of Neurosurgery, Kaiser Permanente Redwood City Medical Center, Redwood City, California (V.A.L.); Department of Neurological Surgery, Ohio State University Comprehensive Cancer Center, Columbus, Ohio (V.K.P.); Department of Neurosurgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah (H.C.); Atlanta Regional Community Clinical Oncology Program, Georgia Cancer Specialists, Canton, Georgia (G.V.-.R.); Department of Neurosciences, Medical University of South Carolina Brain & Spine Tumor Program, Charleston, South Carolina (P.G.); Department of Hematology and Oncology, The University of Kansas Cancer Center, Overland Park, Kansas (M.E.S.); Department of Hematology and Oncology, Saint Francis Medical Center, Cape Girardeau, Missouri (J.D.F.); Department of Neurosurgery, University of Texas Health Science Center, Houston, Texas (S.H.H.); Department of Neurology, West Virginia University, Morgantown, West Virginia (J.G.); Department of Radiation Oncology, Keck School of Medicine, University of Southern California, U.S.C Norris Cancer Hospital, Los Angeles, California (E.L.C.); Department of Radiation Oncology, University of Louisville, James Graham Brown Cancer Center, Louisville, Kentucky (S.Y.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nou155DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288521PMC
February 2015

Getting more out of survival data by using the hazard function.

Clin Cancer Res 2014 Mar 5;20(6):1404-9. Epub 2014 Feb 5.

Authors' Affiliations: Departments of Biostatistics and NeuroOncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-2125DOI Listing
March 2014

Treatment of anaplastic oligodendrogliomas: should resources be used to codify the old or to create the new?

Authors:
Victor A Levin

Oncology (Williston Park) 2013 Apr;27(4):322, 324

Department of Neurosurgery and Neuroscience, Kaiser Permanente, Redwood City, California USA.

View Article

Download full-text PDF

Source
April 2013

Ask the Experts: How best to treat recurrent glioma.

CNS Oncol 2012 Sep;1(1):21-4

Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Centre, Houston, TX, USA; Department of Neurosurgery, UCSF Medical School, San Francisco, CA, USA; Department of Neurosurgery and Neuroscience, Kaiser Permanente Hospital, Redwood City, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/cns.12.3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6176809PMC
September 2012

Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma.

Cancer 2012 Jul 15;118(14):3599-606. Epub 2011 Nov 15.

Department of Neuro-oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.26663DOI Listing
July 2012

A systematic approach to the management of patients with brain metastases of known or unknown primary site.

Cancer Chemother Pharmacol 2012 Jan 1;69(1):1-13. Epub 2011 Nov 1.

Neurosurgical Research Institute, University of Ioannina, 45110 Ioannina, Greece.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00280-011-1775-9
Publisher Site
http://dx.doi.org/10.1007/s00280-011-1775-9DOI Listing
January 2012

Protein and phosphoprotein levels in glioma and adenocarcinoma cell lines grown in normoxia and hypoxia in monolayer and three-dimensional cultures.

Proteome Sci 2012 Jan 25;10(1). Epub 2012 Jan 25.

Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1477-5956-10-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3317865PMC
January 2012

Modulation of glioma risk and progression by dietary nutrients and antiinflammatory agents.

Nutr Cancer 2011 ;63(2):174-84

Neurosurgical Research Institute, University of Ioannina, Ioannina, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/01635581.2011.523807DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3047463PMC
June 2011

An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting.

Cancer Chemother Pharmacol 2011 May 27;67(5):971-83. Epub 2011 Mar 27.

Neurosurgical Research Institute, University of Ioannina, Ioannina 45110, Greece.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s00280-011-1617
Web Search
http://link.springer.com/10.1007/s00280-011-1617-9
Publisher Site
http://dx.doi.org/10.1007/s00280-011-1617-9DOI Listing
May 2011

Optimizing radiology peer review: a mathematical model for selecting future cases based on prior errors.

J Am Coll Radiol 2010 Jun;7(6):431-8

Department of Radiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacr.2010.02.001DOI Listing
June 2010

Reliability and validity of the M. D. Anderson Symptom Inventory-Spine Tumor Module.

J Neurosurg Spine 2010 Apr;12(4):421-30

Department of Integrative Care, School of Nursing, The University of Texas Health Science Center at Houston, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3171/2009.10.SPINE0943DOI Listing
April 2010

Role of bevacizumab therapy in the management of glioblastoma.

Cancer Manag Res 2010 Apr 22;2:97-104. Epub 2010 Apr 22.

Neuro-Oncology Program, Department of Neurosurgery and Neuroscience, Kaiser Permanente, Redwood City, CA, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004572PMC
April 2010

Different changes in protein and phosphoprotein levels result from serum starvation of high-grade glioma and adenocarcinoma cell lines.

J Proteome Res 2010 Jan;9(1):179-91

Departments of Neuro-Oncology, Bioinformatics and Computational Biology, and Blood and Marrow Transplantation, Section of Molecular Hematology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77230, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/pr900392bDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3386607PMC
January 2010

Melding a New 3-Dimensional Agarose Colony Assay with the E(max) Model to Determine the Effects of Drug Combinations on Cancer Cells.

Technol Cancer Res Treat 2009 Apr;8(2):163-76

Department of Neuro-Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77230-1402, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/153303460900800210DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5481785PMC
April 2009

A new preclinical 3-dimensional agarose colony formation assay.

Technol Cancer Res Treat 2008 Aug;7(4):329-34

Department of Neuro-Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77230-1402, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/153303460800700407DOI Listing
August 2008

Optimizing radiotherapy schedules for elderly glioblastoma multiforme patients.

Expert Rev Anticancer Ther 2008 May;8(5):733-41

Department of Radiation Medicine, Arthur G. James Cancer Hospital, The Ohio State University Medical Center, 300 West 10th Avenue, Ste 083A, Columbus, OH 43210, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737140.8.5.733DOI Listing
May 2008

Long-term anti-inflammatory and antihistamine medication use and adult glioma risk.

Cancer Epidemiol Biomarkers Prev 2008 May;17(5):1277-81

Department of Epidemiology, University of Texas MD. Anderson Cancer Center, PO Box 301439, Houston, TX 77230-1439, USA.

View Article

Download full-text PDF

Source
http://cebp.aacrjournals.org/cgi/doi/10.1158/1055-9965.EPI-0
Publisher Site
http://dx.doi.org/10.1158/1055-9965.EPI-07-2621DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6436627PMC
May 2008

Relationship between ornithine decarboxylase levels in anaplastic gliomas and progression-free survival in patients treated with DFMO-PCV chemotherapy.

Int J Cancer 2007 Nov;121(10):2279-83

Department of Neuro-Oncology and M. D. Anderson Clinical Oncology Program, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.22914DOI Listing
November 2007

Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas.

BMC Cancer 2007 Jun 22;7:106. Epub 2007 Jun 22.

Department of Neuro-Oncology, Unit 431, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2407-7-106DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1919386PMC
June 2007

Are gliomas preventable?

Authors:
Victor A Levin

Recent Results Cancer Res 2007 ;174:205-15

Neuro-Oncology Unit 431, University of Texas, M.D. Anderson Cancer Center, Houston 77230-1402, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-540-37696-5_18DOI Listing
March 2007

Effect of bevacizumab on radiation necrosis of the brain.

Int J Radiat Oncol Biol Phys 2007 Feb;67(2):323-6

Department of Neuro-Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230-1402, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S036030160603249
Publisher Site
http://dx.doi.org/10.1016/j.ijrobp.2006.10.010DOI Listing
February 2007

Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status.

J Neurooncol 2006 Oct 25;80(1):83-90. Epub 2006 Apr 25.

Department of Neuro-Oncology, Unit #431, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11060-006-9160-y
Publisher Site
http://dx.doi.org/10.1007/s11060-006-9160-yDOI Listing
October 2006

Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation.

J Neurooncol 2006 Jul 25;78(3):295-302. Epub 2006 Apr 25.

Department of Neuro-Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11060-005-9098-5
Publisher Site
http://dx.doi.org/10.1007/s11060-005-9098-5DOI Listing
July 2006

Headache related to brain tumors.

Curr Treat Options Neurol 2006 Jan;8(1):21-32

Neuro-Oncology Unit 431, UT MD Anderson Cancer Center, PO Box 301402, Houston, TX 77230, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11940-996-0021-yDOI Listing
January 2006

Tissue-based assay for ornithine decarboxylase to identify patients likely to respond to difluoromethylornithine.

J Histochem Cytochem 2004 Nov;52(11):1467-74

Dept. of Neuro-Oncology, Unit 431, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030-4009, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1369/jhc.4A6358.2004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3957822PMC
November 2004

Overview of radiotherapy resources in Latin America: a survey by the International Atomic Energy Agency (IAEA).

Radiother Oncol 2004 Oct;73(1):97-100

Section of Applied Radiation Biology and Radiotherapy, Division of Human Health, Department of Nuclear Applications, International Atomic Energy Agency (IAEA), Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.radonc.2004.07.022DOI Listing
October 2004

Polymorphisms of DNA repair genes and risk of glioma.

Cancer Res 2004 Aug;64(16):5560-3

Department of Epidemiology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-03-2181DOI Listing
August 2004

13-cis-retinoic acid in the treatment of recurrent glioblastoma multiforme.

Neuro Oncol 2004 Jul;6(3):253-8

Department of Neuro-Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1215/S1152851703000607DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1871997PMC
July 2004

Cyclooxygenase-2 inhibitors in glioma therapy.

Am J Ther 2004 Mar-Apr;11(2):141-3

University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/00045391-200403000-00009DOI Listing
June 2004

Basis and importance of Src as a target in cancer.

Authors:
Victor A Levin

Cancer Treat Res 2004 ;119:89-119

Department of Neuro-Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/1-4020-7847-1_6DOI Listing
June 2004

Advances in gene therapy and immunotherapy for brain tumors.

Curr Opin Neurol 2003 Dec;16(6):665-70

Department of Neuro-Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.wco.0000102625.38669.62DOI Listing
December 2003

Stereotactic injection of DTI-015 into recurrent malignant gliomas: phase I/II trial.

Neoplasia 2003 Jan-Feb;5(1):9-16

Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1502123PMC
http://dx.doi.org/10.1016/s1476-5586(03)80012-xDOI Listing
July 2003

Hypofractionated radiotherapy for elderly or younger low-performance status glioblastoma patients: outcome and prognostic factors.

Int J Radiat Oncol Biol Phys 2003 Jun;56(2):519-28

Division of Radiation Oncology, Brain Tumor Center, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0360-3016(02)04522-4DOI Listing
June 2003

Formation of DNA adducts and tumor growth delay following intratumoral administration of DTI-015.

J Neurooncol 2003 May;62(3):251-8

Laboratory of Molecular Therapeutics, Department of Neurological Surgery, Brain Tumor Research Center, University of California, San Francisco, CA 94143-0555, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1023/a:1023383717833DOI Listing
May 2003

Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas.

Clin Cancer Res 2003 Mar;9(3):981-90

Department of Neuro-Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
March 2003

2-Methoxyestradiol interferes with NF kappa B transcriptional activity in primitive neuroectodermal brain tumors: implications for management.

Carcinogenesis 2003 Feb;24(2):209-16

Center for Cancer Causation and Prevention, AMC Cancer Research Center and University of Colorado Comprehensive Cancer Center, Denver, CO 80214, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/carcin/24.2.209DOI Listing
February 2003

Posterior fossa decompression for life-threatening tonsillar herniation in patients with gliomatosis cerebri: report of three cases.

Neurosurgery 2003 Jan;52(1):216-23; discussion 223

Department of Neurosurgery, Brain Tumor Center, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/00006123-200301000-00028DOI Listing
January 2003

Prospective randomized trial of HDR brachytherapy as a sole modality in palliation of advanced esophageal carcinoma--an International Atomic Energy Agency study.

Int J Radiat Oncol Biol Phys 2002 May;53(1):127-33

University of the Witwatersrand, Box 4280, Cresta 2118, Johannesburg, South Africa.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0360-3016(02)02702-5DOI Listing
May 2002

Radiotherapy services in countries in transition: gross national income per capita as a significant factor.

Radiother Oncol 2002 May;63(2):147-50

Section of Applied Radiation Biology and Radiotherapy, Division of Human Health, Department of Nuclear Sciences and Applications, International Atomic Energy Agency (IAEA), Wagramer Strasse 5, P.O. Box 200, A-1400, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0167-8140(02)00010-5DOI Listing
May 2002

Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme.

J Clin Oncol 2002 Mar;20(5):1383-8

Department of Neuro-Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2002.20.5.1383DOI Listing
March 2002